Payment overview · 2025
General Payments
$254.11
14 reported records · 8 companies
Healthcare provider profile · identity verified
Sandy Hemric-Bryant, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MOUNT AIRY, NC · NPI 1205546207
Verified facts
What the public records show
CMS Open Payments records show Sandy Hemric-Bryant, NP received $254.11 in general payments during 2025 across 14 reported records.
Axsome Therapeutics, Inc. accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $79.31 | 31.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.85 | 17.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.28 | 17.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $24.89 | 9.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.29 | 6.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.53 | 6.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.54 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.42 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $254.11 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $79.31 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 122 |
| Gabapentin | Gabapentin | 230 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 115 |
| Omeprazole | Omeprazole | 221 | 106 |
| Lisinopril | Lisinopril | 208 | 103 |
| Losartan Potassium | Losartan Potassium | 192 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 158 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 73 |
| Furosemide | Furosemide | 132 | 73 |
| Metformin Hcl | Metformin Hcl | 128 | 63 |
| Montelukast Sodium | Montelukast Sodium | 126 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 63 |
| Eliquis | Apixaban | 117 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 56 |
| Simvastatin | Simvastatin | 104 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 56 |
| Carvedilol | Carvedilol | 89 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 50 |
| Sertraline Hcl | Sertraline Hcl | 87 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 63 |
| Trazodone Hcl | Trazodone Hcl | 74 | 35 |
| Potassium Chloride | Potassium Chloride | 67 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 60 |
| Ezetimibe | Ezetimibe | 65 | 30 |
| Ozempic | Semaglutide | 63 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 22 |
| Alendronate Sodium | Alendronate Sodium | 50 | 22 |
| Alprazolam | Alprazolam | 49 | 20 |
| Glipizide | Glipizide | 49 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 25 |
| Allopurinol | Allopurinol | 45 | 23 |
| Farxiga | Dapagliflozin Propanediol | 44 | 22 |
| Famotidine | Famotidine | 43 | 28 |
| Spironolactone | Spironolactone | 42 | 17 |
| Metformin Hcl Er | Metformin Hcl | 41 | 20 |
| Fluconazole | Fluconazole | 40 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 15 |
| Jardiance | Empagliflozin | 37 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 18 |
| Januvia | Sitagliptin Phosphate | 35 | 13 |
| Lovastatin | Lovastatin | 35 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Ondansetron Odt | Ondansetron | 33 | 23 |
| Buspirone Hcl | Buspirone Hcl | 32 | 19 |
| Meloxicam | Meloxicam | 32 | 19 |
| Tramadol Hcl | Tramadol Hcl | 32 | 17 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | 12 |
| Nystatin | Nystatin | 29 | 23 |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 14 |
| Linzess | Linaclotide | 27 | 12 |
| Warfarin Sodium | Warfarin Sodium | 27 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 13 |
| Sucralfate | Sucralfate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 14 |
| Azithromycin | Azithromycin | 25 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 15 |
| Ibuprofen | Ibuprofen | 24 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | 12 |
| Atenolol | Atenolol | 23 | 14 |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | 11 |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Estradiol | Estradiol | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 12 |
| Benazepril Hcl | Benazepril Hcl | 19 | 14 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 14 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 15 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $254.11 · 14 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, ENTRESTO, FARXIGA, LEQVIO, VRAYLAR, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error